GLP-1 Peptide Stability Data 2026: Tirzepatide, Semaglutide, Mazdutide, Survodutide, Retatrutide

Technical Comparison | 2026-07-09 | 10 min read

A 2026 comparison of GLP-1 analog stability data: degradation pathways, shelf life, storage conditions, reconstitution stability, and the analytical methods used to characterize stability for tirzepatide, semaglutide, mazdutide, survodutide, and retatrutide.

Why GLP-1 stability data matters for research programs

A peptide that degrades during storage or handling produces inconsistent experimental results. For GLP-1 research programs — where dose-response curves and receptor binding studies depend on knowing the exact active peptide concentration — stability is not a quality checkbox. It is a data integrity requirement.

Each GLP-1 analog has a distinct stability profile determined by its amino acid sequence, modifications, and formulation. Understanding these profiles helps researchers design appropriate handling protocols and interpret COA data correctly.

Primary degradation pathways for GLP-1 analogs

Pathway 1: Oxidation

Methionine residues oxidize to methionine sulfoxide under oxidative stress (peroxide, light, metal ions). In GLP-1 analogs:

Semaglutide: Aib at position 8 replaces Met → no oxidation risk at position 8
Tirzepatide: Aib at position 8 → no oxidation at position 8
Mazdutide: position 8 may be Met or modified → verify with MS

Oxidation reduces receptor binding affinity and can produce false-positive results in receptor activation assays.

Pathway 2: Deamidation

Asparagine (Asn) and Glutamine (Gln) residues deamidate to aspartic acid (Asp) and glutamic acid (Glu) under acidic or neutral conditions. Deamidation rates depend on the flanking sequence:

Asn-Gly sequences deamidate rapidly (weeks at pH 7)
Asn-Ser sequences deamidate moderately
Asn-Ala sequences deamidate slowly

Pathway 3: Hydrolysis

Aspartic acid residues, particularly Asp-Pro bonds, undergo acid-catalyzed hydrolysis. This is accelerated at low pH and elevated temperature. GLP-1 analogs with Asp in their sequences should be handled at neutral pH.

Pathway 4: Aggregation

Peptide aggregation is a physical instability that increases with concentration and temperature. GLP-1 analogs at concentrations above 1-2 mg/mL in aqueous solution can form soluble oligomers or insoluble fibrils. This is a critical issue for in vivo dosing studies:

Aggregated peptide can produce immunogenic responses in animal studies
Aggregation reduces the apparent concentration in dosing solutions
Fibrillar aggregates are difficult to redissolve

Stability data by GLP-1 analog

Semaglutide

| Condition | Observation | | --- | --- | | Lyophilized powder, -20°C, 36 months | ≥98% purity by HPLC | | Lyophilized powder, 2-8°C, 12 months | ≥97% purity | | Reconstituted in PBS pH 7.4, 2-8°C, 28 days | ≥95% purity | | Reconstituted in PBS pH 7.4, RT, 7 days | ≥93% purity | | In aqueous solution at 1 mg/mL, 37°C, 7 days | Minimal aggregation |

Key stability features: Aib at position 8 eliminates Met oxidation. Fatty diacid chain enhances physical stability. One of the most stable GLP-1 analogs.

Tirzepatide

| Condition | Observation | | --- | --- | | Lyophilized powder, -20°C, 24 months | ≥95% purity | | Lyophilized powder, 2-8°C, 12 months | ≥94% purity | | Reconstituted in PBS pH 7.4, 2-8°C, 21 days | ≥95% purity | | Reconstituted in PBS pH 7.4, RT, 7 days | ≥92% purity | | In aqueous solution at 1 mg/mL, 37°C, 7 days | Minor aggregation at high concentration |

Key stability features: Similar to semaglutide. The dual GIP/GLP-1 structure adds one additional degradation pathway (GIP sequence deamidation) but the overall profile is comparable.

Mazdutide

| Condition | Observation | | --- | --- | | Lyophilized powder, -20°C, 18 months | ≥95% purity (limited long-term data) | | Reconstituted in PBS pH 7.4, 2-8°C, 14 days | ≥94% purity | | Forced degradation (oxidative) | Met oxidation if present at position 8 |

Key stability features: Comparable GLP-1/GCGR dual agonist structure to survodutide. Limited long-term stability data available as it is a newer clinical compound.

Survodutide

Key stability features: GLP-1/GCGR dual agonist. Stability profile similar to mazdutide. Limited long-term data available.

Retatrutide

| Condition | Observation | | --- | --- | | Lyophilized powder, -20°C, 12 months | ≥95% purity (limited long-term data) | | Reconstituted in PBS pH 7.4, 2-8°C, 14 days | ≥93% purity | | Aggregation risk | Higher at concentrations >2 mg/mL |

Key stability features: Triple agonist structure adds complexity. The longer sequence and additional modification sites may increase aggregation risk relative to dual agonists.

Analytical methods for GLP-1 stability characterization

| Method | What it detects | | --- | --- | | RP-HPLC | Purity, degradation peaks | | MS (LC-MS) | Oxidation products, deamidation products, mass shifts | | SEC-HPLC | Soluble aggregates, oligomers | | Capillary electrophoresis (iCIEF) | Charge variants (deamidation, oxidation) | | DLS | Particle size, fibril detection | | Visual inspection | Color, morphology | | pH measurement | Formulation stability |

A complete stability study uses RP-HPLC purity as the primary endpoint, with MS confirmation of degradation products and SEC-HPLC for aggregation monitoring.

Best practices for handling GLP-1 peptides in the lab

**Store lyophilized powder at -20°C** — most stable, use desiccant
**Divide reconstituted solutions into single-use aliquots** — avoid repeated freeze-thaw
**Use neutral pH buffers (pH 7.0-7.4)** — minimize deamidation and hydrolysis
**Protect from light** — minimize photo-oxidation
**Verify concentration by UV absorbance** — confirm active peptide concentration before dosing
**Run a purity check before use** — especially for older lots or lots stored above -20°C

ZePeptide provides stability data packages for all GLP-1 analogs, including forced degradation study results and long-term stability data where available.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.

Research peptide catalog Supplier checklist More peptide guides